MiNK Therapeutics, Inc.

As of June 30, 2026, MiNK Therapeutics, Inc. carries a market capitalization of 52.50M, placing it among publicly traded companies globally. Its enterprise value stands at 44.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MiNK Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, MiNK Therapeutics, Inc. has 5.10M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, MiNK Therapeutics, Inc. maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -187.78, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 10.03, while the 200-day moving average is 9.80.

Over the twelve months ended June 30, 2026, MiNK Therapeutics, Inc. generated - - in revenue and converted that into -9.94M in net income, yielding earnings per share of -2.10. EBITDA reached -10.36M, while operating income came in at -10.82M.

These figures are as of June 30, 2026. Total book value stands at -12.28M, with working capital of 1.51M providing operational flexibility.

MiNK Therapeutics, Inc. produced -5.98M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.24: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -23.32, meaning MiNK Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MiNK Therapeutics, Inc.'s most recent stock split took place on January 28, 2025 with a 10:1 split ratio.

As of June 30, 2026, MiNK Therapeutics, Inc. has an Altman Z-Score of -26.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.